AOD-9604vsRetatrutide

AOD-9604 is a modified fragment of human growth hormone comprising amino acids 176-191 with an additional tyrosine residue at the N-terminus. This specific region of the GH molecule contains the lipolytic (fat-burning) domain while lacking the receptor binding regions responsible for growth-promoting and diabetogenic effects. The result is a peptide that mimics the fat metabolism effects of growth hormone without stimulating IGF-1 production, bone growth, or insulin resistance.

The primary mechanism involves stimulation of beta-3 adrenergic receptors on adipocytes, which activates hormone-sensitive lipase (HSL) through a cAMP-dependent pathway. HSL catalyzes the hydrolysis of stored triglycerides into free fatty acids and glycerol, which are then released into the bloodstream for oxidation by muscle and liver tissue. Simultaneously, AOD-9604 appears to inhibit lipogenesis — the synthesis of new fatty acids from non-lipid precursors — by downregulating acetyl-CoA carboxylase and fatty acid synthase activity in adipocytes.

Unlike full-length growth hormone, AOD-9604 does not bind to the GH receptor or stimulate JAK2/STAT5 signaling, which is why it avoids the IGF-1 elevation, water retention, and insulin resistance associated with exogenous GH use. However, it should be noted that AOD-9604 failed to show significant weight loss compared to placebo in Phase II/III clinical trials, raising questions about whether its in vitro lipolytic activity translates to meaningful clinical effects at the doses tested.

Retatrutide is a triple hormone receptor agonist that simultaneously activates GIP, GLP-1, and glucagon receptors — the first molecule to target all three pathways. Each receptor system contributes distinct metabolic effects that combine to produce unprecedented weight loss results in clinical trials.

The GLP-1 component suppresses appetite through hypothalamic signaling and slows gastric emptying, while the GIP component enhances beta-cell insulin secretion and may improve lipid handling in adipose tissue. What sets retatrutide apart is the addition of glucagon receptor agonism. Glucagon receptors in the liver stimulate glycogenolysis, gluconeogenesis, and critically, hepatic fatty acid oxidation. In brown and beige adipose tissue, glucagon signaling drives thermogenesis — literally increasing the body's energy expenditure by converting calories to heat rather than storing them as fat.

The glucagon component also has significant implications for liver health, as it directly promotes the breakdown of hepatic triglycerides, making retatrutide particularly promising for metabolic-associated steatotic liver disease (MASLD/NASH). The molecular design balances the three receptor affinities carefully — too much glucagon agonism could raise blood glucose, but the concurrent GLP-1 and GIP activation provides sufficient insulinotropic counterbalance to maintain glycemic control. Phase 2 trials demonstrated up to 24% body weight reduction at the highest dose, representing the largest weight loss achieved by any anti-obesity medication to date.